Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Receivables - Other (2017 - 2022)

Historic Receivables - Other for Denali Therapeutics (DNLI) over the last 5 years, with Q2 2022 value amounting to $357000.0.

  • Denali Therapeutics' Receivables - Other fell 7721.76% to $357000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $357000.0, marking a year-over-year decrease of 7721.76%. This contributed to the annual value of $1.2 million for FY2021, which is 7839.27% down from last year.
  • Latest data reveals that Denali Therapeutics reported Receivables - Other of $357000.0 as of Q2 2022, which was down 7721.76% from $1.2 million recorded in Q4 2021.
  • In the past 5 years, Denali Therapeutics' Receivables - Other registered a high of $5.7 million during Q4 2020, and its lowest value of $357000.0 during Q2 2022.
  • In the last 4 years, Denali Therapeutics' Receivables - Other had a median value of $1.2 million in 2021 and averaged $2.0 million.
  • In the last 5 years, Denali Therapeutics' Receivables - Other skyrocketed by 15474.14% in 2018 and then tumbled by 7839.27% in 2021.
  • Quarter analysis of 4 years shows Denali Therapeutics' Receivables - Other stood at $1.2 million in 2018, then skyrocketed by 380.03% to $5.7 million in 2020, then tumbled by 78.39% to $1.2 million in 2021, then tumbled by 70.88% to $357000.0 in 2022.
  • Its Receivables - Other stands at $357000.0 for Q2 2022, versus $1.2 million for Q4 2021 and $1.2 million for Q3 2021.